Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynn R Webster

Showing results (71-80 of 131) with videos related to

Pageof 14
Sort By:
Pain Medicine (Malden, Mass.)|September 17, 2016
Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid UsersMichael D Smith, Lynn R Webster, John Lawler, et al.
Pain Medicine (Malden, Mass.)|June 15, 2011
System dynamics modeling as a potentially useful tool in analyzing mitigation strategies to reduce overdose deaths associated with pharmaceutical opioid treatment of chronic painWayne Wakeland, Teresa Schmidt, Aaron M Gilson, et al.
Pain Medicine (Malden, Mass.)|May 10, 2012
Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodoneLynn R Webster, Brad Bath, Robert A Medve, et al.
Journal of Pain Research|March 3, 2021
Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches 5% and Lidocaine Medicated Plaster 5% in Healthy SubjectsJeffrey Gudin, Lynn R Webster, Emileigh Greuber, et al.
Pain Medicine (Malden, Mass.)|September 14, 2022
Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled AnalysisLynn R Webster, Darren Brenner, Robert J Israel, et al.
Pain Medicine (Malden, Mass.)|July 17, 2013
Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomesLynn R Webster, Kieran A Slevin, Arvind Narayana, et al.
Pain Medicine (Malden, Mass.)|August 17, 2017
Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label TrialLynn R Webster, Edward Michna, Arif Khan, et al.
Pain Medicine (Malden, Mass.)|May 21, 2008
Sleep-disordered breathing and chronic opioid therapyLynn R Webster, Youngmi Choi, Himanshu Desai, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|September 28, 2016
Poster 420 Pharmacodynamic Effects from a Category 3 Oral Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid UsersMichael D Smith, Lynn R Webster, John Lawler, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|September 28, 2016
Poster 427 Pharmacodynamic Effects From a Category 3 Intranasal Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid UsersLynn R Webster, Michael D Smith, John Lawler, et al.
Pageof 14

Showing results (71-80 of 131) with videos related to

Sort By:
Pageof 14
Pain Medicine (Malden, Mass.)|September 17, 2016
Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid UsersMichael D Smith, Lynn R Webster, John Lawler, et al.
Pain Medicine (Malden, Mass.)|June 15, 2011
System dynamics modeling as a potentially useful tool in analyzing mitigation strategies to reduce overdose deaths associated with pharmaceutical opioid treatment of chronic painWayne Wakeland, Teresa Schmidt, Aaron M Gilson, et al.
Pain Medicine (Malden, Mass.)|May 10, 2012
Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodoneLynn R Webster, Brad Bath, Robert A Medve, et al.
Journal of Pain Research|March 3, 2021
Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches 5% and Lidocaine Medicated Plaster 5% in Healthy SubjectsJeffrey Gudin, Lynn R Webster, Emileigh Greuber, et al.
Pain Medicine (Malden, Mass.)|September 14, 2022
Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled AnalysisLynn R Webster, Darren Brenner, Robert J Israel, et al.
Pain Medicine (Malden, Mass.)|July 17, 2013
Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomesLynn R Webster, Kieran A Slevin, Arvind Narayana, et al.
Pain Medicine (Malden, Mass.)|August 17, 2017
Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label TrialLynn R Webster, Edward Michna, Arif Khan, et al.
Pain Medicine (Malden, Mass.)|May 21, 2008
Sleep-disordered breathing and chronic opioid therapyLynn R Webster, Youngmi Choi, Himanshu Desai, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|September 28, 2016
Poster 420 Pharmacodynamic Effects from a Category 3 Oral Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid UsersMichael D Smith, Lynn R Webster, John Lawler, et al.
PM & R : the Journal of Injury, Function, and Rehabilitation|September 28, 2016
Poster 427 Pharmacodynamic Effects From a Category 3 Intranasal Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid UsersLynn R Webster, Michael D Smith, John Lawler, et al.
Pageof 14